The novel arylamidine T-2307 demonstrates in vitro and in vivo Activity against Candida auris

Nathan P. Wiederhold; Laura K. Najvar; Rosie Jaramillo; Marcos Olivo; Hoja Patterson; April Connell; Yoshiko Fukuda; Junichi Mitsuyama; Gabriel Catano; Thomas F. Patterson

doi:10.1128/AAC.02198-19

The novel arylamidine T-2307 demonstrates in vitro and in vivo Activity against Candida auris

Nathan P. Wiederhold, Laura K. Najvar, Rosie Jaramillo, Marcos Olivo, Hoja Patterson, April Connell, Yoshiko Fukuda, Junichi Mitsuyama, Gabriel Catano, Thomas F. Patterson

Research output: Contribution to journal › Article › peer-review

36 Scopus citations

Abstract

The in vitro and in vivo activity of the arylamidine T-2307 against Candida auris was evaluated. T-2307 demonstrated in vitro activity (MIC ranges ≤ 0.008 to 0.015 μg/ml at 50% inhibition; 0.125 to >4 μg/ml at 100% inhibition). Treatment with T-2307 (3 mg/kg subcutaneous [SC] once daily) also significantly improved survival (70% at 21 days postinfection) and reduced kidney fungal burden (5.06 log₁₀ CFU/g) compared to control (0% survival and 7.09 log₁₀ CFU/g) (P < 0.01).

Original language	English (US)
Article number	e02198
Journal	Antimicrobial agents and chemotherapy
Volume	64
Issue number	3
DOIs	https://doi.org/10.1128/AAC.02198-19
State	Published - 2020

Keywords

Candida auris
Caspofungin
Fluconazole
In vitro susceptibility
Invasive candidiasis
Murine model
T-2307

ASJC Scopus subject areas

Pharmacology (medical)
Infectious Diseases
Pharmacology

Access to Document

10.1128/AAC.02198-19

Cite this

@article{2c87a22771e54f75841ce85508ff6a27,

title = "The novel arylamidine T-2307 demonstrates in vitro and in vivo Activity against Candida auris",

abstract = "The in vitro and in vivo activity of the arylamidine T-2307 against Candida auris was evaluated. T-2307 demonstrated in vitro activity (MIC ranges ≤ 0.008 to 0.015 μg/ml at 50% inhibition; 0.125 to >4 μg/ml at 100% inhibition). Treatment with T-2307 (3 mg/kg subcutaneous [SC] once daily) also significantly improved survival (70% at 21 days postinfection) and reduced kidney fungal burden (5.06 log10 CFU/g) compared to control (0% survival and 7.09 log10 CFU/g) (P < 0.01).",

keywords = "Candida auris, Caspofungin, Fluconazole, In vitro susceptibility, Invasive candidiasis, Murine model, T-2307",

author = "Wiederhold, {Nathan P.} and Najvar, {Laura K.} and Rosie Jaramillo and Marcos Olivo and Hoja Patterson and April Connell and Yoshiko Fukuda and Junichi Mitsuyama and Gabriel Catano and Patterson, {Thomas F.}",

year = "2020",

doi = "10.1128/AAC.02198-19",

language = "English (US)",

volume = "64",

journal = "Antimicrobial agents and chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "3",

}

TY - JOUR

T1 - The novel arylamidine T-2307 demonstrates in vitro and in vivo Activity against Candida auris

AU - Wiederhold, Nathan P.

AU - Najvar, Laura K.

AU - Jaramillo, Rosie

AU - Olivo, Marcos

AU - Patterson, Hoja

AU - Connell, April

AU - Fukuda, Yoshiko

AU - Mitsuyama, Junichi

AU - Catano, Gabriel

AU - Patterson, Thomas F.

PY - 2020

Y1 - 2020

N2 - The in vitro and in vivo activity of the arylamidine T-2307 against Candida auris was evaluated. T-2307 demonstrated in vitro activity (MIC ranges ≤ 0.008 to 0.015 μg/ml at 50% inhibition; 0.125 to >4 μg/ml at 100% inhibition). Treatment with T-2307 (3 mg/kg subcutaneous [SC] once daily) also significantly improved survival (70% at 21 days postinfection) and reduced kidney fungal burden (5.06 log10 CFU/g) compared to control (0% survival and 7.09 log10 CFU/g) (P < 0.01).

AB - The in vitro and in vivo activity of the arylamidine T-2307 against Candida auris was evaluated. T-2307 demonstrated in vitro activity (MIC ranges ≤ 0.008 to 0.015 μg/ml at 50% inhibition; 0.125 to >4 μg/ml at 100% inhibition). Treatment with T-2307 (3 mg/kg subcutaneous [SC] once daily) also significantly improved survival (70% at 21 days postinfection) and reduced kidney fungal burden (5.06 log10 CFU/g) compared to control (0% survival and 7.09 log10 CFU/g) (P < 0.01).

KW - Candida auris

KW - Caspofungin

KW - Fluconazole

KW - In vitro susceptibility

KW - Invasive candidiasis

KW - Murine model

KW - T-2307

UR - http://www.scopus.com/inward/record.url?scp=85079886634&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85079886634&partnerID=8YFLogxK

U2 - 10.1128/AAC.02198-19

DO - 10.1128/AAC.02198-19

M3 - Article

C2 - 31844006

AN - SCOPUS:85079886634

SN - 0066-4804

VL - 64

JO - Antimicrobial agents and chemotherapy

JF - Antimicrobial agents and chemotherapy

IS - 3

M1 - e02198

ER -

The novel arylamidine T-2307 demonstrates in vitro and in vivo Activity against Candida auris

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this